Dellambra Elena, Carbone Maria Luigia, Ricci Francesca, Ricci Francesco, Di Pietro Francesca Romana, Moretta Gaia, Verkoskaia Sofia, Feudi Elisa, Failla Cristina M, Abeni Damiano, Fania Luca
Molecular and Cell Biology Laboratory, IDI-IRCCS, 00167 Rome, Italy.
Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy.
Biomedicines. 2021 Jun 23;9(7):718. doi: 10.3390/biomedicines9070718.
Merkel cell carcinoma (MCC) is a rare and extremely aggressive neuroendocrine carcinoma of the skin, with increasing incidence worldwide. This review intends to propose a comprehensive evaluation of MCC epidemiology, clinical features, pathogenetic mechanisms, diagnosis, and therapies. A section is dedicated to immunological aspects and another to the involvement of angiogenesis and angiogenic growth factors in MCC progression, proposing novel diagnostic and therapeutic approaches. Advanced MCC tumors have been treated with immune checkpoint inhibitors with effective results. Therefore, the state of art of this immunotherapy is also examined, reporting on the most recent clinical trials in the field. We conclude by underlining the achievements in the understanding of MCC pathology and indicating the present needs for effective diagnosis and therapeutic management of the disease.
默克尔细胞癌(MCC)是一种罕见且极具侵袭性的皮肤神经内分泌癌,在全球范围内发病率呈上升趋势。本综述旨在对MCC的流行病学、临床特征、发病机制、诊断及治疗进行全面评估。其中一部分专门讨论免疫学方面,另一部分则探讨血管生成及血管生成生长因子在MCC进展中的作用,并提出新的诊断和治疗方法。晚期MCC肿瘤已采用免疫检查点抑制剂进行治疗,效果显著。因此,本文还研究了这种免疫疗法的最新进展,报告了该领域最新的临床试验情况。我们在结尾强调了在理解MCC病理学方面所取得的成就,并指出了目前对该疾病进行有效诊断和治疗管理的需求。